(Total Views: 548)
Posted On: 12/22/2022 9:53:59 AM
Post# of 148878
Lots of news in the last few days. Sharing some toughts:
In a way I am happy and, excuse me if I am selfish. I own a substantial number of shares and, currently, risking sleeping in the sofa for a considerable amount of time (until wife files for divorce and I go to the park bench ) in any slip of my tonge. But why I am happy?? I do extensive DD with any investment, with CYDY this meant reading several (understatement) papers and then, waiting for the clinical trials that would show that the drug was effective (or not). This is the name of the game. After investing in 2018 and continuing buying shares thereafter I could not possibly explain to myself why I got this so wrong. Back then there was talk of the BLA being submitted “soon”, and the no-adverse events new super-duper HIV drug approval was imminent.
For all these years I was wondering why the BLA had not been submitted and the drug approved. My initial reaction was that the FDA was stonewalling us as NP skillfully kept the carrot at the front of my face and, knowing that the drug works, I was all ears. I believed because this is what we are “trained” to do. You find a drug that works, you run trials, they are successful, you submit the BLA, the FDA approves, the drug sells, the SP goes higher, you make money and help patients … right???
But there was a big problem: the CRO (AMAREX) was incompetent, our CEO was a crook, inept/unable/unwilling at supervising the CRO and the BOD was nowhere to be seen.
I pose it that it would have been easier to do the right thing, conduct a proper trial and get Leronlimab to the goal, than to go through all this debauchery. There is a saying in my culture that says: It is easier being rich than poor, and better to be free than in the big house. A lot lost on the translation, but you get the point.
I forgot to say why I am happy: because now I can excuse myself for not being wrong about the science of our molecule; I am just not good at detecting charlatans.
But what is next?? Well, we have lost some time and money and are back to square one. We need to decide for which of the indications a clinical trial can be run the fastest and more economically (I am sure we have some trial protocols at the ready). Also, were and how we can get financing (partnerships?). The new CEO and board have little room to maneuver and taking the right decisions is a must.
At the end we will prevail and those buying these days will make a bundle.
Happy holidays to all, let's hope 2022 will bring all of us all we are wishing for.
In a way I am happy and, excuse me if I am selfish. I own a substantial number of shares and, currently, risking sleeping in the sofa for a considerable amount of time (until wife files for divorce and I go to the park bench ) in any slip of my tonge. But why I am happy?? I do extensive DD with any investment, with CYDY this meant reading several (understatement) papers and then, waiting for the clinical trials that would show that the drug was effective (or not). This is the name of the game. After investing in 2018 and continuing buying shares thereafter I could not possibly explain to myself why I got this so wrong. Back then there was talk of the BLA being submitted “soon”, and the no-adverse events new super-duper HIV drug approval was imminent.
For all these years I was wondering why the BLA had not been submitted and the drug approved. My initial reaction was that the FDA was stonewalling us as NP skillfully kept the carrot at the front of my face and, knowing that the drug works, I was all ears. I believed because this is what we are “trained” to do. You find a drug that works, you run trials, they are successful, you submit the BLA, the FDA approves, the drug sells, the SP goes higher, you make money and help patients … right???
But there was a big problem: the CRO (AMAREX) was incompetent, our CEO was a crook, inept/unable/unwilling at supervising the CRO and the BOD was nowhere to be seen.
I pose it that it would have been easier to do the right thing, conduct a proper trial and get Leronlimab to the goal, than to go through all this debauchery. There is a saying in my culture that says: It is easier being rich than poor, and better to be free than in the big house. A lot lost on the translation, but you get the point.
I forgot to say why I am happy: because now I can excuse myself for not being wrong about the science of our molecule; I am just not good at detecting charlatans.
But what is next?? Well, we have lost some time and money and are back to square one. We need to decide for which of the indications a clinical trial can be run the fastest and more economically (I am sure we have some trial protocols at the ready). Also, were and how we can get financing (partnerships?). The new CEO and board have little room to maneuver and taking the right decisions is a must.
At the end we will prevail and those buying these days will make a bundle.
Happy holidays to all, let's hope 2022 will bring all of us all we are wishing for.
(19)
(0)Scroll down for more posts ▼
